Fig. 5: Long term survival of patients (as numbered in Table 1) treated with CART-aIL6/IL1RA. | Cell Discovery

Fig. 5: Long term survival of patients (as numbered in Table 1) treated with CART-aIL6/IL1RA.

From: Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy

Fig. 5

Patients with refractory or relapsed ALL, CLL, Lymphoma or MM were enrolled and treated with anti-CD19 or anti-BCMA CART secreting anti-IL6 scFv and IL1RA. After CART infusion, patients were examined for clinical response of tumor remission, and followed up for evaluating long-term survival. CR complete response, PR partial response, NR no response, Ag+ relapse antigen positive relapse, Ag– relapse antigen negative relapse.

Back to article page